Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DARE-BV1
- Development stage
- Approved
- Lead developer
- Daré Bioscience
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravaginal
01
Overview
DARE-BV1 is a thermosetting bioadhesive hydrogel formulation containing 2% clindamycin phosphate, designed for single-dose intravaginal administration. It is indicated for the treatment of bacterial vaginosis in females aged 12 years and older. The drug acts as an antibacterial agent by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome. Developed by Daré Bioscience, DARE-BV1 demonstrated superior clinical cure rates compared to placebo and existing FDA-approved products in phase 3 trials, with cure rates ranging from approximately 70% to over 80%. Its unique hydrogel formulation aims to improve antibiotic delivery and patient convenience[1][2][3][5].
- Brand names
- XACIATO
- Other names
- clindamycin phosphate vaginal gel 2%
02
Targets
Bacterial 50S ribosomal subunitNeuraminidase
Beyond the preview
Go deeper on DARE-BV1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DARE-BV1.